Long Island Heart - Evidence-Based Strategies for the Prevention and Management of Hyperkalemia - 2019

Melville, NY US
May 18, 2019

Hyperkalemia in patients with Heart Failure (HF) has been associated with adverse outcomes including cardiac arrhythmia and death. In cases of hyperkalemia (>5 mEq/L), paralysis, arrhythmias, and death are more likely to occur, especially when potassium levels exceed 6.5 mEq/L. HF patients are an increased risk of developing hyperkalemia because of the use of certain medications, especially angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), aldosterone receptor antagonists (ARAs), and direct renin inhibitors (DRIs). Data has shown that many practitioners discontinue treatment with ACEi and ARBS when a patient develop hyperkalemia, particularly in those individuals with concurrent kidney disease. In addition, the 2017 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for HF stresses the importance of managing hyperkalemia, however, these recommendations do not include guidance on the use of newly approved potassium binders for the management of hyperkalemia in HF. The program: Evidence-Based Strategies for the Prevention and Management of Hyperkalemia, is designed to improve practitioner knowledge of the prevention and management of hyperkalemia in patients prescribed renin-angiotensin-aldosterone system (RAAS) inhibitors and implement evidence-based recommendations for the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and the prevention and management of hyperkalemia in heart failure patients.

 
 
 

Target Audience

 

 

 

 

Learning Objectives

•    Discuss the utilization of the renin-angiotensin-aldosterone system (RAAS) inhibitors in heart failure 
•    Identify patients with or who are at risk of developing hyperkalemia
•    Review the clinical application of current and emerging potassium-binding agents for hyperkalemia
•    Summarize evidence-based recommendations for the use of renin-angiotensin-aldosterone system (RAAS)         inhibitors and the prevention and management of hyperkalemia in heart failure patient

 
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits™
  • 1.00 AOA Category 2A
  • 1.00 Certificate of Participation
Course opens: 
05/18/2019
Course expires: 
05/18/2019
Event starts: 
05/18/2019 - 6:00pm
Event ends: 
05/18/2019 - 7:15pm
Cost:
$0.00
Rating: 
0
Melville Marriott Long Island Hotel
1350 Walt Whitman Rd
Melville, NY 11747
United States
HOTEL ACCOMMODATIONS:

If hotel accommodations are desired, a negotiated rate from $182 plus tax has been negotiated at the Melville Marriott Long Island Hotel. 

To reserve a room, go to:  Melville Marriott

Accreditation 

“This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Center for Emergency Medical Education and MedEd Consulting."

The Center for Emergency Medical Education (CEME) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians

The Center for Emergency Medical Education (CEME) designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Center for Emergency Medical Education (CEME) designates this activity for a maximum of 1.00

Available Credit

  • 1.00 AMA PRA Category 1 Credits™
  • 1.00 AOA Category 2A
  • 1.00 Certificate of Participation

Accreditation Period

Course opens: 
05/18/2019
Course expires: 
05/18/2019

Price

Cost:
$0.00
Please login or register to take this course.